Cargando…

Yishen Qingli Heluo Granule in the Treatment of Chronic Kidney Disease: Network Pharmacology Analysis and Experimental Validation

BACKGROUND: Chronic kidney disease (CKD) is considered a global public health problem with high morbidity and mortality. Yishen Qingli Heluo granule (YQHG) is representative traditional Chinese medicine (TCM) remedy for clinical treatment of CKD. This study aims to explore the mechanism of YQHG on C...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Xian, Huang, Yiting, Zhu, Sha, Yan, Jin, Gan, Ke, Xu, Zijing, Wang, Shuaishuai, Kang, Xiaoyu, Zhang, Junfeng, Sun, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959874/
https://www.ncbi.nlm.nih.gov/pubmed/35355655
http://dx.doi.org/10.2147/DDDT.S348335
_version_ 1784677258914430976
author Sun, Xian
Huang, Yiting
Zhu, Sha
Yan, Jin
Gan, Ke
Xu, Zijing
Wang, Shuaishuai
Kang, Xiaoyu
Zhang, Junfeng
Sun, Wei
author_facet Sun, Xian
Huang, Yiting
Zhu, Sha
Yan, Jin
Gan, Ke
Xu, Zijing
Wang, Shuaishuai
Kang, Xiaoyu
Zhang, Junfeng
Sun, Wei
author_sort Sun, Xian
collection PubMed
description BACKGROUND: Chronic kidney disease (CKD) is considered a global public health problem with high morbidity and mortality. Yishen Qingli Heluo granule (YQHG) is representative traditional Chinese medicine (TCM) remedy for clinical treatment of CKD. This study aims to explore the mechanism of YQHG on CKD through network pharmacology and experimental validation. METHODS: Traditional Chinese Medicine Systems Pharmacology (TCMSP) database and wide-scale literature mining were applied to screen active compounds of YQHG. Multiple bioinformatic tools and online databases were applied by us to obtain relevant targets of YQHG and CKD. The intersection targets between YQHG and CKD were considered as candidate targets. The compound-target, herb-candidate target and protein–protein interaction networks were constructed and visualized for topological analyses. GO and KEGG enrichment analyses were conducted to determine the biological processes and signaling pathways. Molecular docking was used to verify the reliability of network pharmacology. Finally, pharmacological evaluation was performed to explore the mechanism of YQHG against CKD on a 5/6 nephrectomy model. RESULTS: Seventy-nine candidate targets, ten core biological processes and one key signaling pathway (p53) were screened. PTGS2 was identified as a key target based on H-CT network. The molecular docking showed that Quercetin, Kaempferol, Luteolin were three key compounds with the best binding activity. In addition, IL6 and Quercetin could form a stable complex with high binding affinity (−7.29 kcal/mol). In vivo experiment revealed that YQHG improved kidney function and fibrosis in 5/6 nephrectomized rats. Moreover, the decreased expression of PTGS2, IL6, and the increased expression of p53 were observed in kidney tissue. Notably, the gut microbiota of rats treated with YQHG was reshaped, which was characterized by a reduced ratio of Firmicutes/Bacteroidota. CONCLUSION: Our results predicted and verified the potential targets of YQHG on CKD from a holistic perspective, and provided valuable direction for the further research of YQHG.
format Online
Article
Text
id pubmed-8959874
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-89598742022-03-29 Yishen Qingli Heluo Granule in the Treatment of Chronic Kidney Disease: Network Pharmacology Analysis and Experimental Validation Sun, Xian Huang, Yiting Zhu, Sha Yan, Jin Gan, Ke Xu, Zijing Wang, Shuaishuai Kang, Xiaoyu Zhang, Junfeng Sun, Wei Drug Des Devel Ther Original Research BACKGROUND: Chronic kidney disease (CKD) is considered a global public health problem with high morbidity and mortality. Yishen Qingli Heluo granule (YQHG) is representative traditional Chinese medicine (TCM) remedy for clinical treatment of CKD. This study aims to explore the mechanism of YQHG on CKD through network pharmacology and experimental validation. METHODS: Traditional Chinese Medicine Systems Pharmacology (TCMSP) database and wide-scale literature mining were applied to screen active compounds of YQHG. Multiple bioinformatic tools and online databases were applied by us to obtain relevant targets of YQHG and CKD. The intersection targets between YQHG and CKD were considered as candidate targets. The compound-target, herb-candidate target and protein–protein interaction networks were constructed and visualized for topological analyses. GO and KEGG enrichment analyses were conducted to determine the biological processes and signaling pathways. Molecular docking was used to verify the reliability of network pharmacology. Finally, pharmacological evaluation was performed to explore the mechanism of YQHG against CKD on a 5/6 nephrectomy model. RESULTS: Seventy-nine candidate targets, ten core biological processes and one key signaling pathway (p53) were screened. PTGS2 was identified as a key target based on H-CT network. The molecular docking showed that Quercetin, Kaempferol, Luteolin were three key compounds with the best binding activity. In addition, IL6 and Quercetin could form a stable complex with high binding affinity (−7.29 kcal/mol). In vivo experiment revealed that YQHG improved kidney function and fibrosis in 5/6 nephrectomized rats. Moreover, the decreased expression of PTGS2, IL6, and the increased expression of p53 were observed in kidney tissue. Notably, the gut microbiota of rats treated with YQHG was reshaped, which was characterized by a reduced ratio of Firmicutes/Bacteroidota. CONCLUSION: Our results predicted and verified the potential targets of YQHG on CKD from a holistic perspective, and provided valuable direction for the further research of YQHG. Dove 2022-03-24 /pmc/articles/PMC8959874/ /pubmed/35355655 http://dx.doi.org/10.2147/DDDT.S348335 Text en © 2022 Sun et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Sun, Xian
Huang, Yiting
Zhu, Sha
Yan, Jin
Gan, Ke
Xu, Zijing
Wang, Shuaishuai
Kang, Xiaoyu
Zhang, Junfeng
Sun, Wei
Yishen Qingli Heluo Granule in the Treatment of Chronic Kidney Disease: Network Pharmacology Analysis and Experimental Validation
title Yishen Qingli Heluo Granule in the Treatment of Chronic Kidney Disease: Network Pharmacology Analysis and Experimental Validation
title_full Yishen Qingli Heluo Granule in the Treatment of Chronic Kidney Disease: Network Pharmacology Analysis and Experimental Validation
title_fullStr Yishen Qingli Heluo Granule in the Treatment of Chronic Kidney Disease: Network Pharmacology Analysis and Experimental Validation
title_full_unstemmed Yishen Qingli Heluo Granule in the Treatment of Chronic Kidney Disease: Network Pharmacology Analysis and Experimental Validation
title_short Yishen Qingli Heluo Granule in the Treatment of Chronic Kidney Disease: Network Pharmacology Analysis and Experimental Validation
title_sort yishen qingli heluo granule in the treatment of chronic kidney disease: network pharmacology analysis and experimental validation
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959874/
https://www.ncbi.nlm.nih.gov/pubmed/35355655
http://dx.doi.org/10.2147/DDDT.S348335
work_keys_str_mv AT sunxian yishenqingliheluogranuleinthetreatmentofchronickidneydiseasenetworkpharmacologyanalysisandexperimentalvalidation
AT huangyiting yishenqingliheluogranuleinthetreatmentofchronickidneydiseasenetworkpharmacologyanalysisandexperimentalvalidation
AT zhusha yishenqingliheluogranuleinthetreatmentofchronickidneydiseasenetworkpharmacologyanalysisandexperimentalvalidation
AT yanjin yishenqingliheluogranuleinthetreatmentofchronickidneydiseasenetworkpharmacologyanalysisandexperimentalvalidation
AT ganke yishenqingliheluogranuleinthetreatmentofchronickidneydiseasenetworkpharmacologyanalysisandexperimentalvalidation
AT xuzijing yishenqingliheluogranuleinthetreatmentofchronickidneydiseasenetworkpharmacologyanalysisandexperimentalvalidation
AT wangshuaishuai yishenqingliheluogranuleinthetreatmentofchronickidneydiseasenetworkpharmacologyanalysisandexperimentalvalidation
AT kangxiaoyu yishenqingliheluogranuleinthetreatmentofchronickidneydiseasenetworkpharmacologyanalysisandexperimentalvalidation
AT zhangjunfeng yishenqingliheluogranuleinthetreatmentofchronickidneydiseasenetworkpharmacologyanalysisandexperimentalvalidation
AT sunwei yishenqingliheluogranuleinthetreatmentofchronickidneydiseasenetworkpharmacologyanalysisandexperimentalvalidation